番茄、番茄红素及相关产品对血压的影响:系统评价和网络荟萃分析。

Effect of tomato, lycopene and related products on blood pressure: A systematic review and network meta-analysis.

机构信息

Faculty of Pharmacy, Mahidol University, Bangkok, Thailand.

Faculty of Pharmacy, Srinakharinwirot University, Nakhon Nayok, Thailand.

出版信息

Phytomedicine. 2021 Jul 15;88:153512. doi: 10.1016/j.phymed.2021.153512. Epub 2021 Feb 16.

Abstract

BACKGROUND

A number of randomized controlled trials (RCTs) have been conducted to evaluate the hypotensive effects of tomato, lycopene, and related products. However, the findings were conflicting, partly due to differences in the types of products investigated. Therefore, this study aimed to assess and compare the hypotensive effects of different tomato-related preparations through a network meta-analysis based on randomized controlled trials.

STUDY DESIGN

A systematic review and network meta-analysis.

METHODS

A network meta-analysis based on a systematic review of RCTs comparing the effect of various tomato, lycopene and related products versus placebo on blood pressure in adults was performed. PubMed, EMBASE, SCOPUS, and Clinicaltrial.gov databases were searched up to October 2020 without language restrictions. The primary outcomes were systolic and diastolic blood pressure. Mean differences (MDs) along with 95% confidence intervals (CIs) were estimated and pooled using a random-effects model. Heterogeneity was assessed using the global inconsistency test.

RESULTS

A total of 11 studies including six forms of tomato, lycopene and related products met the inclusion criteria. Among these trials, eight (N = 617) and seven trials (N = 501) were included in the analysis of systolic (SBP) and diastolic blood pressure (DBP) outcomes, respectively. The standardized tomato extract (STE) significantly decreased SBP compared to placebo, with a pooled MD (95% CI) of -5.89 (-9.13 to -2.64) mmHg. The effect on DBP was not significant, with a pooled MD (95% CI) of -3.51 (-7.39 to 0.38) mmHg. Subgroup analysis in hypertensive patients showed that STE significantly reduced both SBP and DBP with pooled MDs (95% CIs) of -8.09 (-11.52 to -4.67) and -4.25 (-6.97 to -1.53) mmHg, respectively, compared to placebo. Other forms of tomato, including other dose ranges of standardized tomato extract, tomato-containing diet, lycopene-free preparation, and synthetic lycopene, did not show consistent and significant effects on either SBP or DBP in all analyses.

CONCLUSION

Standardized tomato extract (STE) significantly decreased SBP compared to placebo in a mixed population of healthy volunteers and hypertensive patients. The BP-lowering effect was more pronounced among hypertensive patients. No significant BP effects were seen with other forms of tomato, lycopene and related products in the overall population or any subgroup of the population.

摘要

背景

多项随机对照试验(RCT)已经评估了番茄、番茄红素及相关产品的降压作用。然而,这些研究结果存在差异,部分原因在于所研究产品的类型不同。因此,本研究旨在通过基于随机对照试验的网状荟萃分析来评估和比较不同番茄相关制剂的降压效果。

研究设计

系统评价和网状荟萃分析。

方法

基于比较各种番茄、番茄红素及相关产品与安慰剂对成年人血压影响的 RCT 的系统评价,进行网状荟萃分析。检索了 PubMed、EMBASE、SCOPUS 和 Clinicaltrial.gov 数据库,检索时间截至 2020 年 10 月,未设语言限制。主要结局指标为收缩压和舒张压。使用随机效应模型,采用均值差(MD)及其 95%置信区间(CI)进行估计和合并。使用全局不一致性检验评估异质性。

结果

共有 11 项研究符合纳入标准,其中包括 6 种形式的番茄、番茄红素及相关产品。在这些试验中,8 项(N=617)和 7 项试验(N=501)分别被纳入收缩压(SBP)和舒张压(DBP)结局分析。标准化番茄提取物(STE)与安慰剂相比,显著降低 SBP,合并 MD(95%CI)为-5.89(-9.13 至-2.64)mmHg。对 DBP 的影响不显著,合并 MD(95%CI)为-3.51(-7.39 至 0.38)mmHg。高血压患者的亚组分析显示,与安慰剂相比,STE 显著降低 SBP 和 DBP,合并 MD(95%CI)分别为-8.09(-11.52 至-4.67)和-4.25(-6.97 至-1.53)mmHg。其他形式的番茄,包括标准化番茄提取物的不同剂量范围、含番茄的饮食、不含番茄红素的制剂和合成番茄红素,在所有分析中对 SBP 或 DBP 均未显示出一致和显著的影响。

结论

标准化番茄提取物(STE)与安慰剂相比,在健康志愿者和高血压患者的混合人群中显著降低 SBP。降压效果在高血压患者中更为明显。在总体人群或任何亚组人群中,其他形式的番茄、番茄红素及相关产品对血压均无显著影响。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索